Insider trade

Officer sold ~$116K of GILD shares in the open market

Traded Sep 15, 2026 · Filed Sep 16, 2026

~$116K
Reported value · 800 sh @ $144.4569: 117K
Holds after · shares reported: +0.8%
stock since the trade · S&P 500 +0.9%, $146.30 → $147.50 on Oct 1

Why it stands out

Gilead Sciences's Chief Comm & Corp Aff Officer sold $116K of Gilead Sciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 15, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 16, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$115,566

Shares × reported transaction price

Timing vs results

42 days after results of Aug 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $146.30 on Sep 15, 2026, 32% above its 52-week low and 6% below its high, after a 12% rise over the previous 30 trading days

52-week range $110.56 (Oct 2, 2025) to $155.80 (Feb 11, 2026), 79% of the way up, from 251 adjusted closes. 30 trading days earlier: $131.15 on Aug 3, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Bixlenvo Sunlenca Starter Pack (Copackaged) on Aug 27, 2026, 19 days before this trade.

New drug application approved. Active ingredient: Bictegravir Sodium, Lenacapavir Sodium, Lenacapavir Sodium. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-0.8%	+0.6%	-1.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001782135-26-000033
Filed / recorded: Sep 16, 2026, 8:27 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: GILEAD SCIENCES, INC.
Issuer CIK: 882095
Ticker: GILD
Reporting person: Johanna Mercier
Relationship: Officer
Officer title: Chief Comm & Corp Aff Officer
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 15, 2026
Transaction code: S
Shares / units: 800
Price per share: $144.4569
Acquired / disposed: Disposed (D)
Shares owned after: 117,284
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
Sale prices for the transactions reported range from $144.26 to $144.775. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Around the same time

CEO sold ~$1.77M of Gilead Sciences

Scheduled in advance3d ago

CEO sold ~$446K of Gilead Sciences

Scheduled in advance3d ago

13d ago

2,223Shares

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record